NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$112.94 -2.11 (-1.83 %)
(As of 01/17/2019 03:49 AM ET)
Previous Close$115.05
Today's Range$112.61 - $119.5110
52-Week Range$91.56 - $325.98
Volume168,813 shs
Average Volume220,283 shs
Market Capitalization$1.76 billion
P/E Ratio-44.46
Dividend YieldN/A
Beta1.32
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263

Debt

Current Ratio73.69
Quick Ratio73.69

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Book Value$13.02 per share
Price / Book8.67

Profitability

Net Income$-31,150,000.00
Net MarginsN/A
Return on Assets-8.78%

Miscellaneous

Employees8
Market Cap$1.76 billion
OptionableOptionable

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) posted its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.03. View Madrigal Pharmaceuticals' Earnings History.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Madrigal Pharmaceuticals.

What price target have analysts set for MDGL?

12 brokers have issued 1-year price targets for Madrigal Pharmaceuticals' shares. Their forecasts range from $124.00 to $400.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $262.6250 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.

What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

News coverage about MDGL stock has trended positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of Madrigal Pharmaceuticals' key competitors?

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the folowing people:
  • Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 76)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $112.94.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.76 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is http://www.madrigalpharma.com.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]


MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel